Researchers studying the effect of the monoclonal antibody Leronlimab on long COVID-19 may have found a surprising clue to the baffling syndrome, one that contradicts their initial hypothesis. An abnormally suppressed immune system may be to blame, not a persistently hyperactive one as they had suspected.
As families prepare to gather later this month for Thanksgiving, it is important for patients who are immunocompromised to take extra steps to protect themselves from becoming infected with COVID-19. People who are immunocompromised have weakened immune systems, which means they have a higher risk of becoming severely ill from COVID-19.
Researchers published interim results in The New England Journal of Medicine from a Phase 3 study of the COVID-19 monoclonal antibody treatment sotrovimab, sponsored by Vir Biotechnology and GlaxoSmithKline. The study found that compared to the placebo group, COVID-19 patients who received sotrovimab had a significantly reduced risk of hospitalization or death and that the treatment, which was administered by intravenous infusion on an outpatient basis, was safe.
A new analysis by a team of physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) provides the first evidence that monoclonal antibodies were indeed underutilized in the first six months of FDA authorization.
In a large observational study, Mayo Clinic researchers have shown that two monoclonal antibodies administered separately helped prevent hospitalization in high-risk patients who became infected with COVID-19. The study also showed more hospitalizations were observed among patients with more comorbidities. The findings appear in The Journal of Infectious Diseases.
A study from Washington University School of Medicine in St. Louis suggests that many, but not all, COVID-19 therapies made from combinations of two antibodies are effective against a wide range of virus variants, and that combination therapies appear to prevent the emergence of drug resistance.
Treating transplant patients with mild to moderate cases of COVID-19 with monoclonal antibodies is safe and helps prevent serious illness, according to a Mayo Clinic study recently published in Open Forum Infectious Diseases. These results are especially important because transplant patients who are infected with COVID-19 have a higher risk of severe illness and death.
Houston Methodist announced today, in partnership with the U.S. Department of Health and Human Services (HHS), that it has expanded access to COVID-19 monoclonal antibody therapy (mAb) in the Greater Houston area. The promising treatment has been shown to keep high-risk COVID-19 patients out of the hospital and reduce the likelihood of progression to severe disease.
The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai
Atlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.
A Michigan Medicine team’s online guidelines have been viewed more than 30,000 times by providers in 150 countries since the beginning of the pandemic–and their deployment of an effective COVID-19 therapy has been a model for health systems and hospitals statewide.
A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.
A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.
Antibody-based drugs have been authorized for emergency use in COVID-19 patients by the Food and Drug Administration. Researchers at Washington University School of Medicine in St. Louis have discovered that the ability to interact with other elements of the immune system is an indispensable part of the effectiveness of such antibodies. The findings could help improve the design of the next generation of antibody-based COVID-19 drugs.
UVA Health is offering monoclonal antibody drugs for appropriate patients with COVID-19 who are at highest risk for developing severe symptoms and requiring hospitalization.
In this free STS webinar, Next Steps in Eradicating COVID-19: Emerging Treatments and Vaccines, STS President Dr. Joseph Dearani will talk with infectious disease experts from the White House Coronavirus Task Force and Mayo Clinic about promising new treatments and preventive measures.
COVID-19 and Monoclonal Antibodies – Emergency Use Authorization for Bamlanivimab The FDA’s Emergency Use Authorization to treat high risk COVID-19 patients with the monoclonal antibody bamlanivimab will offer limited availability in Texas, where only 6,000 government doses are expected next…
Keck Medicine of USC is enrolling individuals in a phase 3 clinical trial to test monoclonal antibody treatment for COVID-19
Researchers at the University of Illinois Chicago are now enrolling people into a phase 3 clinical trial that will test if a monoclonal antibody treatment — administered as a series of four shots — will help protect uninfected individuals from acquiring or getting sick from COVID-19 after someone in the household tests positive for COVID-19.
When Christina Loville tested positive for the coronavirus, she was terrified. She decided to channel her fear into researching COVID-19 treatments, where she discovered a local clinical trial led by experts at The University of Texas Health Science Center at Houston (UTHealth).
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
SEATTLE — Oct. 5, 2020 — Fred Hutchinson Cancer Research Center announced the opening of the COVID-19 Clinical Research Center, or CCRC. Funded by philanthropic donations and public/private partnerships, the CCRC is one of the first stand-alone facilities in the nation designed to test novel interventions to treat and prevent COVID-19.
A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.
A study on the effectiveness of multiple treatments, including laboratory-made antibodies, at preventing mild COVID-19 from advancing to severe illness in the outpatient setting is underway by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.
On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.
The National Institutes of Health will soon launch a phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.